| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P819 | ADS bibcode | 2014PLoSO...9j7926S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0107926 |
| P932 | PMC publication ID | 4178055 |
| P698 | PubMed publication ID | 25260023 |
| P5875 | ResearchGate publication ID | 266241901 |
| P2093 | author name string | Ming Li | |
| Jianzhong Ma | |||
| Huidan Zhang | |||
| Lianfeng Shan | |||
| P2860 | cites work | Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. | Q54585853 |
| Different real time PCR approaches for the fine quantification of SNP's alleles in DNA pools: assays development, characterization and pre-validation. | Q54638669 | ||
| Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis | Q75244904 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study | Q83801480 | ||
| Molecular origins of cancer: Molecular basis of colorectal cancer | Q24617331 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Quantitative and sensitive detection of rare mutations using droplet-based microfluidics | Q28238121 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| High-throughput droplet digital PCR system for absolute quantitation of DNA copy number | Q28251729 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. | Q33903874 | ||
| Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes | Q33947043 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients | Q34994963 | ||
| PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. | Q35953893 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Q36628049 | ||
| DxS Ltd. | Q37126666 | ||
| The molecular therapy of colorectal cancer | Q37695708 | ||
| Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples | Q38284922 | ||
| Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. | Q38412630 | ||
| The allele-specific probe and primer amplification assay, a new real-time PCR method for fine quantification of single-nucleotide polymorphisms in pooled DNA. | Q40872268 | ||
| Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology | Q41907272 | ||
| The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. | Q46140702 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. | Q54509870 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| monoclonal antibody | Q422248 | ||
| ras subfamily | Q424396 | ||
| ErbB receptors | Q5385089 | ||
| colorectal neoplasm | Q58833976 | ||
| proto-oncogene protein | Q66020913 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e107926 | |
| P577 | publication date | 2014-09-26 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis | |
| P478 | volume | 9 |
| Q61814489 | Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study |
| Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
| Q48009778 | Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes |
Search more.